Sun Pharma Advanced Research Company Reports Mixed Financial Results for June 2025

Aug 04 2025 03:17 PM IST
share
Share Via
Sun Pharma Advanced Research Company (SPARC) has released its financial results for the quarter ending June 2025, showcasing a mix of achievements and challenges. While operating profit and profit after tax reached five-quarter highs, net sales fell to their lowest level in the same period, alongside rising interest expenses.
Sun Pharma Advanced Research Company (SPARC) has recently reported its financial results for the quarter ending June 2025, revealing notable trends within its performance metrics. The evaluation changes indicate a shift in the company's overall score, which has moved to a lower position compared to the previous three months.

On a positive note, SPARC has recorded its highest operating profit (PBDIT) in the last five quarters, amounting to Rs -52.08 crore. Similarly, the profit after tax (PAT) has also reached its peak at Rs -51.87 crore during the same period, suggesting a near-term positive trend in profitability. Additionally, earnings per share (EPS) have shown improvement, with the latest figure at Rs -1.60, reflecting an increase in earnings for shareholders.

Conversely, the company has faced challenges, particularly in net sales, which have fallen significantly to Rs 9.64 crore, marking the lowest level in five quarters. This decline represents a substantial drop compared to the average net sales of the previous four quarters. Furthermore, interest expenses have risen to Rs 6.19 crore, the highest in the last five quarters, indicating increased borrowing costs.

Overall, SPARC's financial results highlight a complex landscape of both positive developments and significant challenges.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News